Metabolic Optimization · Reviewed by Ian K. Tseng, MD

What Is Semaglutide? How the GLP-1 Mechanism Works

Semaglutide is the compound that pulled the word "peptide" into everyday conversation. Underneath the noise is a specific, well-described mechanism: it imitates a gut hormone your body already makes. Here is what that means physiologically, what a physician screens for before prescribing it, and why the delivery route and dose schedule matter as much as the molecule.

Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director

Soothe IV Med Spa branded amber pharmacy vial on warm marble, representing the metabolic optimization category of physician-supervised peptide therapy

The short answer

Semaglutide is a 31-amino-acid analog of GLP-1, a hormone your gut releases after you eat. It binds the same receptor and produces the same downstream signals — glucose-dependent insulin release, suppressed glucagon, slower gastric emptying, and reduced appetite signaling in the hypothalamus. Structural modifications make it resist the enzyme that normally breaks GLP-1 down in minutes, which is why it is dosed once weekly rather than continuously.

The incretin system, in plain terms

When food reaches your small intestine, specialized cells release hormones called incretins. The best studied is glucagon-like peptide-1 — GLP-1. Its job is to coordinate the body's response to a meal: tell the pancreas to release insulin, but only when glucose is actually elevated; suppress glucagon, the hormone that raises blood sugar; slow the rate at which the stomach empties; and signal satiety to the brain.

Natural GLP-1 is remarkably short-lived. An enzyme called dipeptidyl peptidase-4 (DPP-4) degrades it within roughly one to two minutes. That brevity is fine for meal-by-meal signaling but makes native GLP-1 useless as a therapy — you cannot dose something with a two-minute half-life.

Semaglutide is engineered around exactly that problem. It shares about 94% of its structure with human GLP-1, with two changes: a substitution at the site DPP-4 attacks, and a fatty-acid chain that lets the molecule bind reversibly to albumin in the blood. Bound to albumin, it circulates protected. The result is a half-life of roughly one week.

Why "glucose-dependent" is the important phrase

The insulin release semaglutide promotes is glucose-dependent — the signal only fires meaningfully when blood glucose is already elevated. This is mechanistically different from older diabetes drugs that push insulin regardless of glucose level, and it is the reason the hypoglycemia risk profile differs between drug classes. It is not zero risk, particularly when combined with other glucose-lowering medications, which is one of the specific interactions a prescribing physician reviews.

The appetite effect operates through a separate pathway. GLP-1 receptors are expressed in regions of the hypothalamus and brainstem involved in satiety and food-reward signaling. Patients frequently describe the subjective experience as food simply occupying less mental space — what the literature sometimes calls a reduction in "food noise."

Side effects, titration, and why dose escalation is slow

The most commonly reported adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are largely a direct consequence of the intended mechanism — slowed gastric emptying is doing what it is designed to do. They are typically dose-dependent and most pronounced during dose escalation.

This is the clinical reason protocols start at a low dose and escalate on a schedule over weeks rather than starting at a therapeutic dose. Skipping titration reliably produces a worse experience without producing faster results. A physician-managed protocol builds the escalation schedule around your tolerance and adjusts it when side effects appear.

Less common but clinically significant considerations include pancreatitis, gallbladder disease, and effects on kidney function in the setting of dehydration from persistent vomiting. GLP-1 receptor agonists as a class carry a warning regarding thyroid C-cell tumors observed in rodent studies; the class is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Whether that history exists is one of the first things an intake form asks.

The labs a physician reviews first

A responsible metabolic protocol is bloodwork-gated. The baseline panel typically includes hemoglobin A1c, fasting glucose and insulin, a comprehensive metabolic panel covering kidney and liver function, a lipid panel, and thyroid function. Where clinically indicated, additional markers are added.

The point of the panel is not paperwork. It establishes whether a metabolic therapy is appropriate at all, identifies contraindications, and creates the baseline against which follow-up labs are compared. Our companion article on why peptide therapy starts with bloodwork walks through each marker and what it rules in or out.

FDA-approved versus compounded

This distinction matters and is frequently blurred online. Semaglutide exists in FDA-approved, commercially manufactured products prescribed for specific approved indications. It also exists in compounded preparations produced by compounding pharmacies. These are not the same regulatory category, and a compounded preparation has not been through FDA pre-market review.

Whether a commercially manufactured or compounded product is appropriate for a given patient is a clinical decision made by the prescribing physician based on individual need and current pharmacy availability — not a marketing choice. We do not make claims comparing compounded preparations to any branded product.

Frequently asked questions

What does semaglutide actually do in the body?

It binds the GLP-1 receptor and reproduces the signals of the natural gut hormone GLP-1: glucose-dependent insulin secretion, suppression of glucagon, slowed gastric emptying, and satiety signaling in the hypothalamus and brainstem. Structural modifications protect it from the DPP-4 enzyme that degrades natural GLP-1 within minutes, extending its half-life to roughly one week.

Why is semaglutide dosed once a week instead of daily?

A fatty-acid chain on the molecule binds reversibly to albumin in the bloodstream, and a substitution at the DPP-4 cleavage site prevents rapid enzymatic breakdown. Together these extend the half-life to approximately seven days, which supports once-weekly dosing rather than the continuous dosing natural GLP-1 would require.

Why do protocols start at a low dose?

The gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — are dose-dependent and most pronounced during escalation. Starting low and escalating on a schedule over weeks improves tolerability without changing the eventual therapeutic dose. A physician-managed protocol adjusts the escalation schedule based on how you respond.

Who should not take a GLP-1 receptor agonist?

The class is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Additional caution applies with a history of pancreatitis, gallbladder disease, significant gastrointestinal motility disorders, or concurrent use of other glucose-lowering medications. A physician screens for all of these during the Good Faith Exam.

Is compounded semaglutide the same as the FDA-approved product?

No. FDA-approved products have been through pre-market review for specific indications. Compounded preparations have not. They are different regulatory categories, and data from clinical trials on FDA-approved medications should not be used to make assessments about compounded medications. Which is appropriate for a given patient is a clinical decision made by the prescribing physician.

Clinical references

Medically reviewed by Ian K. Tseng, MD, Medical Director of Soothe IV's peptide therapy program. The clinical statements in this article are supported by the following sources:

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art. Molecular Metabolism. 2021. pmc.ncbi.nlm.nih.gov
Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology. 2019. pmc.ncbi.nlm.nih.gov
U.S. Food & Drug Administration. Human Drug Compounding. www.fda.gov

Ready to talk to a physician?

Start your $50 Application — the comprehensive intake, physician Good Faith Examination, and medical clearance. A physician reviews your goals and labs and tells you honestly whether therapy is appropriate. Your fee credits in full toward your first month of membership. Available nationwide.

Book & Pay for Your $50 Application

Serving Orange County, Los Angeles, and San Diego — plus nationwide telehealth. All service areas.

This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available nationwide via telehealth; prescriptions are issued by physicians licensed in your state.